{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+Urinary+Bladder&page=2",
    "query": {
      "condition": "Malignant Tumor of Urinary Bladder",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+Urinary+Bladder&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T16:37:24.378Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05230186",
      "title": "A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Tumor Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2021-02-26",
      "completion_date": "2024-12-23",
      "has_results": false,
      "last_update_posted_date": "2022-02-09",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05230186"
    },
    {
      "nct_id": "NCT04075305",
      "title": "The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Oncology",
        "Breast Cancer",
        "Prostate Cancer",
        "Gynecologic Cancer",
        "Brain Tumor",
        "Brain Cancer",
        "Gynecologic Tumor",
        "Prostate Tumor",
        "Prostate Neoplasm",
        "Breast Tumor",
        "Radiation Toxicity",
        "Quality of Life",
        "Rectal Cancer",
        "Rectal Tumor",
        "Rectal Neoplasms",
        "Lung Cancer",
        "Lung Tumor",
        "Lung Neoplasm",
        "Esophageal Cancer",
        "Esophagus Cancer",
        "Esophageal Tumor",
        "Esophageal Neoplasm",
        "Esophagus Tumor",
        "Esophagus Neoplasm",
        "Pancreatic Cancer",
        "Pancreatic Tumor",
        "Pancreatic Neoplasms",
        "Head and Neck Cancer",
        "Head and Neck Neoplasms",
        "Head and Neck Tumor",
        "Tumor",
        "Neoplasms",
        "Bladder Cancer",
        "Bladder Neoplasm",
        "Liver Cancer",
        "Liver Neoplasms",
        "Liver Metastases",
        "Oligometastases"
      ],
      "interventions": [
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "UMC Utrecht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8000,
      "start_date": "2019-02-01",
      "completion_date": "2030-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 3,
      "location_summary": "Pittsburgh, Pennsylvania • Houston, Texas • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04075305"
    },
    {
      "nct_id": "NCT03229278",
      "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Renal Cell Cancer",
        "Recurrent Bladder Carcinoma",
        "Recurrent Classical Hodgkin Lymphoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Renal Cell Carcinoma",
        "Stage III Bladder Cancer",
        "Stage III Lymphoma",
        "Stage III Non-Small Cell Lung Cancer AJCC v7",
        "Stage III Renal Cell Cancer",
        "Stage III Skin Melanoma",
        "Stage IIIA Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Skin Melanoma",
        "Stage IV Bladder Cancer",
        "Stage IV Lymphoma",
        "Stage IV Non-Small Cell Lung Cancer AJCC v7",
        "Stage IV Renal Cell Cancer",
        "Stage IV Skin Melanoma",
        "Stage IVA Bladder Cancer",
        "Stage IVB Bladder Cancer",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Enzyme Inhibitor Therapy",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-10-03",
      "completion_date": "2022-10-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03229278"
    },
    {
      "nct_id": "NCT04383938",
      "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Gastric Cancer",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Urothelial Carcinoma",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "APR-246 (eprenetapopt) + Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aprea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-06-25",
      "completion_date": "2022-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04383938"
    },
    {
      "nct_id": "NCT03138967",
      "title": "Investigation of Sugammadex in Outpatient Urological Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Malignant Neoplasms of Urinary Tract",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Rocuronium",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2017-09-18",
      "completion_date": "2019-11-24",
      "has_results": true,
      "last_update_posted_date": "2020-09-22",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03138967"
    },
    {
      "nct_id": "NCT04306900",
      "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "TTX-030, budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab and docetaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and budigalimab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Trishula Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 185,
      "start_date": "2020-03-30",
      "completion_date": "2024-03-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04306900"
    },
    {
      "nct_id": "NCT05179824",
      "title": "Tempus Priority Study: A Pan-tumor Observational Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Prostate Cancer",
        "Bladder Cancer",
        "Lung Cancer",
        "Brain Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Cancer of Liver",
        "Cancer of Colon",
        "Cancer of Head and Neck",
        "Cancer of Stomach",
        "Cancer of Gastrointestinal Tract",
        "Cancer of Rectum",
        "Cancer of Esophagus",
        "Cancer of Skin",
        "Cancer of Cervix",
        "Cancer of Kidney",
        "Cancer of Larynx",
        "Cancer of Endometrium",
        "Cancer of the Bile Duct",
        "Cancer of Vulva",
        "Cancer of Bone and Connective Tissue",
        "Leukemia",
        "Lymphoma",
        "Spinal Cord Cancer"
      ],
      "interventions": [
        {
          "name": "Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Tempus AI",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2020-10-19",
      "completion_date": "2030-10-19",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05179824"
    },
    {
      "nct_id": "NCT04424641",
      "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumor(s)",
        "Prostate Cancer",
        "Esophageal Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "Squamous Cell Carcinoma of Head and Neck (SCCHN)",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Bladder Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-07-15",
      "completion_date": "2021-10-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04424641"
    },
    {
      "nct_id": "NCT05819827",
      "title": "Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer",
        "Prostate Cancer",
        "Testicular Cancer",
        "Bladder Carcinoma",
        "Genitourinary System Carcinoma",
        "Malignant Testicular Neoplasm",
        "Melanoma",
        "Prostate Carcinoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Blood and Tissue",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2023-04-19",
      "completion_date": "2024-05-21",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05819827"
    },
    {
      "nct_id": "NCT04410302",
      "title": "Patient-Derived Xenografts to Reduce Cancer Health Disparities",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Carcinoma",
        "Gastric Carcinoma",
        "Liver and Intrahepatic Bile Duct Carcinoma",
        "Lung Carcinoma",
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "21 Years to 100 Years"
      },
      "enrollment_count": 500,
      "start_date": "2019-11-12",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-07-23T16:37:24.378Z",
      "location_count": 2,
      "location_summary": "Orange, California • Sacramento, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04410302"
    }
  ]
}